ECSP13012825A - Tableta oralmente desintegradora - Google Patents

Tableta oralmente desintegradora

Info

Publication number
ECSP13012825A
ECSP13012825A ECSP13012825A ECSP13012825A EC SP13012825 A ECSP13012825 A EC SP13012825A EC SP13012825 A ECSP13012825 A EC SP13012825A EC SP13012825 A ECSP13012825 A EC SP13012825A
Authority
EC
Ecuador
Prior art keywords
preparation
granules
medicament
detaching
orally
Prior art date
Application number
Other languages
English (en)
Spanish (es)
Inventor
Yutaka Tanoue
Tetsuya Matsuura
Yutaka Yamagata
Naoki Nagahara
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45567081&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP13012825(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of ECSP13012825A publication Critical patent/ECSP13012825A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
ECSP13012825 2011-01-17 2013-08-13 Tableta oralmente desintegradora ECSP13012825A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011007371 2011-01-17
JP2011227333 2011-10-14

Publications (1)

Publication Number Publication Date
ECSP13012825A true ECSP13012825A (es) 2013-10-31

Family

ID=45567081

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP13012825 ECSP13012825A (es) 2011-01-17 2013-08-13 Tableta oralmente desintegradora

Country Status (24)

Country Link
US (6) US20120282191A1 (enExample)
EP (1) EP2665465A1 (enExample)
JP (3) JP5600747B2 (enExample)
KR (1) KR20140014134A (enExample)
CN (1) CN103429223A (enExample)
AR (1) AR084865A1 (enExample)
AU (1) AU2012207818B2 (enExample)
BR (1) BR112013017600A2 (enExample)
CA (1) CA2824430A1 (enExample)
CL (1) CL2013002033A1 (enExample)
CO (1) CO6791611A2 (enExample)
CR (1) CR20130380A (enExample)
EA (1) EA201391053A1 (enExample)
EC (1) ECSP13012825A (enExample)
IL (1) IL227357A0 (enExample)
MA (1) MA34908B1 (enExample)
MX (1) MX2013008314A (enExample)
PE (1) PE20140255A1 (enExample)
PH (1) PH12013501512A1 (enExample)
SG (1) SG191964A1 (enExample)
TW (1) TW201309347A (enExample)
UY (1) UY33869A (enExample)
WO (1) WO2012099260A1 (enExample)
ZA (1) ZA201305567B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9532952B2 (en) 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
WO2012103411A2 (en) 2011-01-28 2012-08-02 Zx Pharma, Llc Controlled-release melatonin composition and related methods
JP6245677B2 (ja) * 2012-01-20 2017-12-13 ニプロ株式会社 口腔内崩壊錠
CN103989643B (zh) * 2013-07-26 2018-10-30 武汉先路医药科技有限公司 含有雷美替胺和共聚维酮的片剂
KR102272442B1 (ko) * 2013-07-31 2021-07-02 인텔젠스 코프. 계면활성제 또는 폴리알콜을 포함하지 않은 즉각적 습윤성의 경구용 필름 제형
IL276030B (en) * 2014-02-07 2022-09-01 Sentar Pharmaceuticals Inc Non-toxic systems, from natural materials, for administering medicine under the tongue
CN105853379A (zh) * 2016-03-31 2016-08-17 北京万全德众医药生物技术有限公司 一种雷美替胺分散片及其制备工艺
CN106389361A (zh) * 2016-03-31 2017-02-15 北京万全德众医药生物技术有限公司 一种含有雷美替胺的口腔崩解片及其制备方法
US10342873B2 (en) 2016-05-06 2019-07-09 Physician's Seal, LLC Valerian composition and related methods
CN106038502A (zh) * 2016-07-01 2016-10-26 北京万全德众医药生物技术有限公司 一种雷美替胺口崩片及其制备方法
WO2019011290A1 (en) * 2017-07-13 2019-01-17 Maxinase Life Sciences Limited PHARMACEUTICAL COMPOSITIONS OF RAMELTEON AND METHODS OF USE
US11648201B2 (en) 2018-05-02 2023-05-16 Ferring B.V. Pharmaceutical formulations
JP7552146B2 (ja) * 2019-08-28 2024-09-18 小野薬品工業株式会社 イバブラジンを含有する錠剤
CN113243444A (zh) 2020-02-13 2021-08-13 罗盖特公司 作为口香糖中的填充剂的多孔淀粉
JP7611556B2 (ja) * 2020-05-28 2025-01-10 日医工株式会社 服用性、安定性等に優れた医薬組成物
CN115778925A (zh) * 2022-12-26 2023-03-14 湖北广济医药科技有限公司 一种雷美替胺口溶膜剂及其制备方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2884153B2 (ja) * 1996-03-08 1999-04-19 武田薬品工業株式会社 三環性化合物、その製造法および剤
US6034239A (en) 1996-03-08 2000-03-07 Takeda Chemical Industries, Ltd. Tricyclic compounds, their production and use
WO1997047287A1 (en) * 1996-06-14 1997-12-18 Kyowa Hakko Kogyo Co., Ltd. Intraorally rapidly disintegrable tablet
JP3460538B2 (ja) 1997-10-08 2003-10-27 救急薬品工業株式会社 速溶性フィルム製剤
CN1195500C (zh) * 1998-05-18 2005-04-06 武田药品工业株式会社 可口腔崩解的片剂
ATE283708T1 (de) 1999-02-15 2004-12-15 Sumitomo Pharma Im mundraum schnellzerfallende tabletten
US6663883B1 (en) 1999-08-26 2003-12-16 Takeda Chemical Industries, Ltd. Matrix adhering to nasal mucosa
AU2001248751A1 (en) 2000-04-12 2001-10-23 Banyu Pharmaceutical Co. Ltd. Compositions disintegrating in oral cavity and preparations disintegrating in oral cavity
US7008642B1 (en) * 2001-02-12 2006-03-07 Advanced Cardiovascular Systems, Inc. Compositions for achieving a therapeutic effect in an anatomical structure and methods of using the same
KR20040037138A (ko) * 2001-09-28 2004-05-04 가부시키가이샤산와카가쿠켄큐쇼 유핵형 속용붕괴성 성형품
FR2834890B1 (fr) 2002-01-23 2004-02-27 Servier Lab Composition pharmaceutique orodispersible d'agomelatine
US20040161459A1 (en) * 2002-12-31 2004-08-19 Ngoc Do Fast-dissolve tablet technology
WO2008127609A1 (en) * 2007-04-11 2008-10-23 Mccarty John A Melatonin tablet and methods of preparation and use
US20050137247A1 (en) * 2003-12-22 2005-06-23 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of hypertension
GEP20105001B (en) 2005-04-04 2010-06-10 Takeda Pharmaceuticals Co Preventive or remedy for depression or anxiety neurosis
US20100011960A1 (en) * 2005-07-18 2010-01-21 Colin Lawrence Electrostatic Air Filter
PE20070698A1 (es) * 2005-11-14 2007-08-17 Teijin Pharma Ltd Comprimido de disgregacion rapida intraoral que contiene hidrocloruro de ambroxol
FR2894475B1 (fr) 2005-12-14 2008-05-16 Servier Lab Composition pharmaceutique orodispersible pour administra- -tion oromucosale ou sublinguale d'agomelatine
WO2007074856A1 (ja) * 2005-12-28 2007-07-05 Takeda Pharmaceutical Company Limited 口腔内崩壊性固形製剤の製造法
EP2029136A4 (en) 2006-05-22 2010-01-06 Vanda Pharmaceuticals Inc TREATMENT FOR DEPRESSION DISEASES
US7797869B2 (en) * 2006-07-10 2010-09-21 Tollis David R Multi-section display and utility stanchion
WO2008083204A2 (en) * 2006-12-28 2008-07-10 Braincells, Inc. Modulation of neurogenesis by melatoninergic ligands
CA2680536A1 (en) 2007-03-13 2008-10-09 Dainippon Sumitomo Pharma Co., Ltd. Oral disintegrating tablet
WO2009060318A2 (en) * 2007-07-12 2009-05-14 Teva Pharmaceutical Industries Ltd. Polymorphic forms of ramelteon and processes for preparation thereof
JP2009114113A (ja) * 2007-11-06 2009-05-28 Nipro Corp 口腔内崩壊錠及びその製造方法
JP2009136240A (ja) 2007-12-10 2009-06-25 Lion Corp チューインガム組成物
CN102065845A (zh) 2008-06-11 2011-05-18 阿斯利康(瑞典)有限公司 含有(2s)-(4e)-n-甲基-5-(5-异丙氧基吡啶-3-基)-戊-4-烯-2-胺的舌下组合物
US7833819B2 (en) * 2008-07-23 2010-11-16 Aptina Imaging Corporation Method and apparatus for decreasing storage node parasitic charge in active pixel image sensors
WO2010074753A1 (en) * 2008-12-23 2010-07-01 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds
JP2011007371A (ja) 2009-06-23 2011-01-13 Sanyo Electric Co Ltd 空気調和機
JP5513936B2 (ja) * 2010-03-10 2014-06-04 全星薬品工業株式会社 口腔内崩壊製剤
JP5523913B2 (ja) 2010-04-21 2014-06-18 スタンレー電気株式会社 光源装置および照明装置

Also Published As

Publication number Publication date
AU2012207818B2 (en) 2015-05-14
AR084865A1 (es) 2013-07-10
NZ613265A (en) 2015-08-28
CL2013002033A1 (es) 2014-01-03
AU2012207818A1 (en) 2013-05-02
TW201309347A (zh) 2013-03-01
US8642649B2 (en) 2014-02-04
CO6791611A2 (es) 2013-11-14
US20120282191A1 (en) 2012-11-08
ZA201305567B (en) 2014-10-29
SG191964A1 (en) 2013-08-30
CR20130380A (es) 2013-10-09
PE20140255A1 (es) 2014-03-11
JP5600747B2 (ja) 2014-10-01
EA201391053A1 (ru) 2013-12-30
MA34908B1 (fr) 2014-02-01
US20140235709A1 (en) 2014-08-21
CA2824430A1 (en) 2012-07-26
US20130035384A1 (en) 2013-02-07
JP2014198723A (ja) 2014-10-23
JP2016053094A (ja) 2016-04-14
BR112013017600A2 (pt) 2016-10-18
PH12013501512A1 (en) 2013-09-16
US20140235879A1 (en) 2014-08-21
IL227357A0 (en) 2013-09-30
CN103429223A (zh) 2013-12-04
WO2012099260A1 (en) 2012-07-26
JP2013544230A (ja) 2013-12-12
US20130035385A1 (en) 2013-02-07
EP2665465A1 (en) 2013-11-27
UY33869A (es) 2012-08-31
US8642648B2 (en) 2014-02-04
MX2013008314A (es) 2013-09-26
KR20140014134A (ko) 2014-02-05
US20170065553A1 (en) 2017-03-09

Similar Documents

Publication Publication Date Title
ECSP13012825A (es) Tableta oralmente desintegradora
CO6300931A2 (es) Composiciones farmaceuticas que comprenden particulas de liberacion controlada con un nucleo que comprende farmacos levemente basicos
BR112013019223A2 (pt) forma de dosagem para liberação modificada, processo para a fabricação de um comprimido e processo para a fabricação de uma forma de dosagem oral
UY33062A (es) Comprimidos y composiciones farmacéuticas comprimibles recubiertos y métodos de fabricación
BRPI0714539B8 (pt) processo para obtenção de forma de dosagem farmaceutica de liberação prolongada de opioides
CL2014002795A1 (es) Una formulacion de farmaco de liberacion retardada oral para suministrar un farmaco al colon que comprende un nucleo y un recubrimiento para el nucleo, el nucleo comprende un farmaco y el recubrimiento comprende una capa exterior con una mezcla de un primer y segundo material polimerico y una capa interior con un tercer material polimerico; y su metodo de preparacion.
DOP2010000273A (es) Preparacion solida de desintegracion oral
WO2012131463A3 (en) Controlled release pharmaceutical dosage forms
BRPI0712353B8 (pt) comprimidos sublinguais de analgésicos de opióide de dose baixa e processo de preparação
CR11864A (es) Preparación de formas farmacéuticas relajantes de músculos esqueléticos de liberación controlada
BR112012024312A2 (pt) anticorpos biespecíficos
MX391480B (es) Formulaciones farmaceuticas que comprenden pilocarpina.
PH12015501015A1 (en) Pharmaceutical compositions comprising hydromorphone and naloxone
PH12014501218A1 (en) Dry coated tablet
CL2016002560A1 (es) Forma de dosificación farmacéutica sólida oral que comprende siponimod, un agente protector de la humedad y opcionalmente un excipiente farmacéutico; procedimiento de preparación.
CL2008002479A1 (es) Composicion farmaceutica que comprende: a) una o mas sustancias medicamentosas, b) un lipido, c) un co-lipido y d) un mejorador de flujo; formulacion en polvo seco; procesos de elaboracion.
IN2015DN04161A (enExample)
CL2015000390A1 (es) Preparación farmacéutica sólida que contiene levotiroxina sodica, gelatina, acido citrico y un relleno; proceso para la produccion de la preparacion farmaceutica
CL2013001770A1 (es) Proceso para la fabricacion de productos autoclavado de fibrocemento; y producto autoclavado de fibrocemento.
BR112014019526B8 (pt) Forma de dosagem de liberação rápida e seu método de produção
BR112017011314A2 (pt) microcápsula, processo para produzir microcápsulas, dispersão aquosa, e, uso de uma microcápsula.
EA201500044A1 (ru) Лекарственная форма для высвобождения действующих веществ
PH12018502287A1 (en) Moisture-proof tablet containing choline alfoscerate and method for producing the same
TN2013000286A1 (en) Orally dispersible tablet
MX2017015322A (es) Composicion farmaceutica oral de isotretinoin.